Literature DB >> 20525548

Pancreatic insulinoma: current issues and trends.

Dennis Vaidakis1, John Karoubalis, Theodora Pappa, George Piaditis, George N Zografos.   

Abstract

BACKGROUND: Although insulinomas are very rare tumors, they are the most common pancreatic neuroendocrine neoplasms. The incidence in general population is 1-4 per 1,000,000 yearly but the incidence is higher in autopsy studies. The malignancy of insulinomas is difficult to be predicted on the basis of their histological features, and the current WHO classification has been re-evaluated. This review aimed to summarize classical knowledge with current trends in the diagnosis and treatment of insulinomas. DATA SOURCES: A Medline search using terms "insulinoma", "treatment" and "neuroendocrine tumors" was conducted. Additional references were sourced from key articles.
RESULTS: Surgery is the treatment of choice for insulinoma and has an extremely high success rate. Medical treatment is also available but only for patients who are unable or unwilling to undergo surgical treatment. Preoperative localization is necessary for planning the surgical approach. Many methods exist for localization of an insulinoma and can be invasive and non-invasive. The combination of biphasic thin section helical CT and endoscopic ultrasonography (EUS) has an almost 100% sensitivity in localizing insulinomas. Laparoscopic ultrasound is mandatory to localize intraoperatively these tumors. EUS-guided fine needle tattooing is an alternative method of localization in case of lack of laparoscopic ultrasound.
CONCLUSION: Laparoscopic resection for benign insulinomas is the procedure of choice, whereas pancreatectomy is reserved for large, potentially malignant tumors.

Entities:  

Mesh:

Year:  2010        PMID: 20525548

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  28 in total

Review 1.  The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors.

Authors:  Simon Schimmack; Bernhard Svejda; Benjamin Lawrence; Mark Kidd; Irvin M Modlin
Journal:  Langenbecks Arch Surg       Date:  2011-01-28       Impact factor: 3.445

2.  Using the Secretion Ratios of Insulin and C-peptide During the 2-h Oral Glucose Tolerance Test to Diagnose Insulinoma.

Authors:  Jing Liao; Fei Ding; Wei Luo; Xin Nie; Yong He; Guixing Li
Journal:  Dig Dis Sci       Date:  2020-06-11       Impact factor: 3.199

3.  Hepatic arterial infusion combined with systemic chemotherapy induced complete response of metachronous liver metastases after resection of pancreatic insulinoma.

Authors:  Yuki Kiyozumi; Hiroshi Takamori; Osamu Nakahara; Yoshiaki Ikuta; Akira Chikamoto; Toru Beppu; Hideo Baba
Journal:  Clin J Gastroenterol       Date:  2013-11-20

4.  Hypoglycaemia in a 94-year-old man without diabetes.

Authors:  Dustin James Mullens; Jay H Shubrook
Journal:  BMJ Case Rep       Date:  2014-05-20

Review 5.  Pancreatic neuroendocrine tumors.

Authors:  Shailesh V Shrikhande; Bhawna Sirohi; Mahesh Goel; Savio G Barreto
Journal:  Indian J Gastroenterol       Date:  2012-10-03

6.  Malignant Insulinoma: A Rare Form of Neuroendocrine Tumor.

Authors:  Alaa Sada; Amy E Glasgow; Adrian Vella; Geoffrey B Thompson; Travis J McKenzie; Elizabeth B Habermann
Journal:  World J Surg       Date:  2020-07       Impact factor: 3.352

Review 7.  Laparoscopic resection of pancreatic neuroendocrine tumors.

Authors:  Abbas Al-Kurd; Katya Chapchay; Simona Grozinsky-Glasberg; Haggi Mazeh
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

8.  Anesthetic management of insulinoma.

Authors:  Leena Harshad Parate; Nagaraj Mungasuvalli Channappa; Tejesh Channasandra Anandaswamy; Bharath Srinivasaiah
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2015 Jul-Sep

9.  Serum chromogranin A levels for the diagnosis and follow-up of well-differentiated non-functioning neuroendocrine tumors.

Authors:  Yuejuan Cheng; Zhao Sun; Chunmei Bai; Xiaoyan Yan; Ran Qin; Changting Meng; Hongyan Ying
Journal:  Tumour Biol       Date:  2015-09-26

10.  Management of malignant insulinoma.

Authors:  J C Ferrer-García; V Iranzo González-Cruz; S Navas-DeSolís; M Civera-Andrés; C Morillas-Ariño; A Merchante-Alfaro; C Caballero-Díaz; C Sánchez-Juan; C Camps Herrero
Journal:  Clin Transl Oncol       Date:  2013-03-05       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.